Internationaal schreef op 17 december 2014 16:32:
[...]
Het artikel van verwijzing 34 zegt het volgende over veiligheid van Ruconest:
"Safety of rhC1INH
No patient was discontinued because of an adverse reaction. TEAEs occurred less frequently in the rhC1INH groups (27 TEAEs in 7 patients treated with 100 U/kg and 6 TEAEs in 4 patients of the 50 U/kg group; see this article's Table E13, Table E14 in the Online Repository at
www.jacionline.org) than in the saline group (33 TEAEs in 14 patients). One TEAE possibly or probably related to study medication administration occurred in the rhC1INH 100 U/kg dose group compared with 3 in the saline group. Events that were assessed as related to study treatment in patients exposed to rhC1INH were headache and vertigo; events that were assessed as related to study treatment in the patients receiving placebo were headache, injection site swelling, epistaxis, and hypotension. One serious AE (colitis 31 days after treatment) occurred in the rhC1INH 100 U/kg dose group, no serious AE in the 50 U/kg group, and 3 in the saline group. None of these serious AEs were considered by the investigator to be possibly, probably, or definitely related to study drug. There were no clinically relevant changes in hematology, routine chemistry or urinalysis results, electrocardiogram, and vital signs parameters.
Postexposure levels of antirabbit milk protein antibodies were below the cutoff level of the assay for all patients treated with rhC1INH except for 1 patient treated with 50 U/kg rhC1INH, who had antibodies on 1 occasion just above the cutoff level value, but tested negative in a confirmatory displacement assay.
No change in anti-C1INH antibodies pre-exposure and postexposure was detected. Pre-exposure to rhC1INH, 2 patients had IgG antibodies against C1INH just above the cutoff level of the assay. Postexposure samples were negative in all patients except for 2 who showed just above cutoff values on a single occasion. All samples with above cutoff values of IgG against C1INH tested negative in an assay for neutralizing antibodies (results not shown). Results for IgM or IgA anti-C1INH antibodies determinations were all negative, both pre-exposure and postexposure."
J Allergy Clin Immunol. 2010 Oct;126(4):821-827.e14. doi: 10.1016/j.jaci.2010.07.021.
Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema.
Zuraw B1, Cicardi M, Levy RJ, Nuijens JH, Relan A, Visscher S, Haase G, Kaufman L, Hack CE.
Met name de opmerking: "There were no clinically relevant changes in hematology..." lijkt mij duidelijk i.v.m. de vraag over trombose.
Je kunt hem trouwens hier nalezen.
www.jacionline.org/article/S0091-6749...Verwijzing 35
Heb ik niet volledig beschikbaar - maar de abstract geeft al op dit punt helderheid: "no thromboembolic events, anaphylaxis, or neutralizing antibodies were observed"